227
Participants
Start Date
June 30, 2015
Primary Completion Date
November 24, 2020
Study Completion Date
August 31, 2021
Combination of MK3475 with Metronomic CP
"Combination of MK3475 with Metronomic CP. Metronomic CP (cyclophosphamide) will be administered per os bi-daily (50 mg x 2), and given on a week on/ week off schedule.~MK3475 will be administered intraveinously, and given every 3 weeks on day 8. A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation."
Combination of MK3475 with Metronomic CP and G100
"Combination of MK3475 with Metronomic CP and G100. Metronomic CP (cyclophosphamide) will be administered per os bi-daily (50 mg x 2), and given on a week on/ week off schedule.~MK3475 will be administered intravenously (200 mg), and given every 3 weeks on day 8.~G100 will be administered by intra-tumoral injection (20µg), one weekly injection for at least 6 weeks and for a maximum of 12 weeks. G100 will start one week before CP administration (impregnation phase).~A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation."
Institut Paoli Calmettes, Marseille
Institut Claudius Regaud, Toulouse
Institut Bergonié, Bordeaux
Institut de Cancérologie de l'Ouest, Saint-Herblain
Centre Oscar Lambret, Lille
Centre Léon Bérard, Lyon
Institut Curie, Paris
Institut Gustave Roussy, Villejuif
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
Ministry of Health, France
OTHER_GOV
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
INDUSTRY
Institut Bergonié
OTHER